Developing a new targeted therapy for treatment of metastic prostate cancer: synthesis and preclinical validation of sphingosine inhibitor-docetaxel combination nanoparticles

Cooper, Colin (Principal Investigator)
Pshezhetskiy, Dmitry (Co-Investigator)

Status	Finished
Effective start/end date	16/09/13 → 31/07/17

Funding

Prostate Cancer UK: £249,997.99

2 Article

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
Alshaker, H., Wang, Q., Böhler, T., Mills, R., Winkler, M., Arafat, T., Kawano, Y. & Pchejetski, D., 14 Jun 2017, In: Scientific Reports. 7, 3493.
Research output: Contribution to journal › Article › peer-review

Open Access
File

27 Citations (Scopus)

18 Downloads (Pure)
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
Wang, Q., Alshaker, H., Böhler, T., Srivats, S., Chao, Y., Cooper, C. & Pchejetski, D., 19 Jul 2017, In: Scientific Reports. 7, 5901.
Research output: Contribution to journal › Article › peer-review

Open Access
File

84 Citations (Scopus)

57 Downloads (Pure)